Efficacy and Safety of FOLFIRINOX in Patients with Metastatic Pancreatic Cancer![]() Efficacy and Safety of FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Richard M Goldberg, MD (6/23/10) and Malcolm J Moore, MD (6/21/10)
Conroy T et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. Proc ASCO 2010;Abstract 4010. |